)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Kiora Pharmaceuticals (KPRX) investor relations material
Kiora Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary7 Nov, 2025
Executive summary
Advanced two Phase 2 clinical trials: KLARITY for retinal inflammation and ABACUS-2 for vision restoration in retinitis pigmentosa, with lead candidates KIO-301 and KIO-104 in clinical development.
KIO-301 received Orphan Drug Designation in the US and EU, and is in Phase 2 trials for retinitis pigmentosa, with all R&D expenses reimbursed by partner TOI.
Entered a $16M global licensing deal (excluding Asia) with Théa Open Innovation (TOI) for KIO-301, with up to $285M in milestones and tiered royalties.
Signed an exclusive option agreement with Senju for KIO-301 in Asia, receiving $1.25M upfront and potential for $109.5M in future payments plus royalties.
Maintained a diversified pipeline targeting rare and common retinal diseases, expanding trial enrollment and geographic footprint.
Financial highlights
Ended Q3 2025 with $19.4M in cash, cash equivalents, and short-term investments.
Reported $16.0M in collaboration revenue for the nine months ended September 30, 2025, with Q3 2025 collaboration revenue also at $16M.
Net loss of $4.3M for the nine months ended September 30, 2025, but reported net income of $27K for Q3 2025, reflecting favorable tax impacts and noncash gains.
Operating expenses increased to $8.9M from $5.5M year-over-year, driven by higher R&D and G&A costs, with R&D expenses at $2.7M before $1.7M in reimbursements in Q3 2025.
Received $1.2M in reimbursed R&D expenses from Théa and billed $1.5M for additional reimbursable R&D.
Outlook and guidance
Sufficient cash and investments to fund planned operations into late 2027, with potential for further extension through partnership milestones.
Anticipates continued operating losses as clinical development progresses and commercialization infrastructure is built.
KLARITY sentinel assessment status?
Contingent consideration gain drivers?
Next partnership milestones for runway?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Kiora Pharmaceuticals earnings date
Q4 202524 Mar, 2026
Next Kiora Pharmaceuticals earnings date
Q4 202524 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Kiora Pharmaceuticals Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic diseases. The company’s pipeline includes therapies targeting eye conditions such as dry eye disease, retinal disorders, and ocular inflammation. Kiora develops both small molecules and biologics aimed at addressing unmet medical needs in vision care. The company conducts clinical trials and engages in research partnerships to advance its product candidates. Kiora Pharmaceuticals Inc is headquartered in Encinitas, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage